Evidence map›Paper›PMID 40175404›Full record

ArticleNPJ vaccines2025

Post-exposure vaccine protection of CTH522/CAF

Nina Dieu Nhien Tran Nguyen, Sharmila Subratheepam, Safia Guleed, Kristoffer Mazanti Melchiors, Anja Weinreich Olsen, Katharina Wørzner, Frank Follmann, Jes Dietrich

Abstract read
In one paragraph

Article in NPJ vaccines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Nina Dieu Nhien Tran NguyenStatens Serum Institut, Department of Infectious Disease Immunology, Copenhagen, Denmark.
Sharmila SubratheepamStatens Serum Institut, Department of Infectious Disease Immunology, Copenhagen, Denmark.
Safia GuleedStatens Serum Institut, Department of Infectious Disease Immunology, Copenhagen, Denmark.
Kristoffer Mazanti MelchiorsStatens Serum Institut, Department of Infectious Disease Immunology, Copenhagen, Denmark.
Anja Weinreich OlsenStatens Serum Institut, Department of Infectious Disease Immunology, Copenhagen, Denmark.
Katharina WørznerStatens Serum Institut, Department of Infectious Disease Immunology, Copenhagen, Denmark.
Frank FollmannStatens Serum Institut, Department of Infectious Disease Immunology, Copenhagen, Denmark.
Jes DietrichStatens Serum Institut, Department of Infectious Disease Immunology, Copenhagen, Denmark. jdi@ssi.dk.

Funding

Sundhed og Sygdom, Det Frie Forskningsråd Project ID: DFF - 2032-00012B
6 · The paper itself

Abstract

Chlamydia trachomatis (C.t.) is globally the most common sexually transmitted bacterium with an estimated 131 million new cases occurring every year. There is no licenced vaccine against C.t. Repeated infections are often observed in women, suggesting that natural immunity is only partially protective. It is therefore important to investigate if a vaccine given post exposure, on top of a partially protective natural immunity, can increase protection against reinfection. In mice, an infection leads to robust immunity to subsequent challenges that precludes an investigation of increased protection elicited by a post-exposure vaccine. Therefore, we developed a new animal model where the first infection only provided partial protection against reinfection. Using this model, we show that UV-SvD/CAF

Identifiers

PMID40175404
PMCPMC11965518

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.